# A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial

> **NCT05133349** · PHASE2 · UNKNOWN · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Advanced or Metastatic Paraganglioma/ Pheochromocytoma

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT05133349
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-14
- **Primary completion:** 2023-09-14
- **Final completion:** 2023-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05133349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05133349, "A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05133349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*